Trial
NCT03699384
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Pfizer
Condition
Acute Myeloid Leukemia (AML)
Intervention
Azacitidine
Why stopped
Study sponsor discontinued support
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-02-20